A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 51; no. 1; pp. 115 - 121
• Main Authors: Leighl, Natasha B., Tsao, W. Stephen, Zawisza, Dianne L., Nematollahi, Mahsan, Shepherd, Frances A.
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 2006; Elsevier Science
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - economics; Carcinoma, Non-Small-Cell Lung - pathology; Cost; Cost of Illness; Erlotinib; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - economics; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Neoplasm Staging; Patient Compliance; Pneumology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - economics; Quinazolines - administration & dosage; Quinazolines - economics; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Retrospective Studies; Treatment Outcome; Tumors of the respiratory system and mediastinum; Utility; Willingness-to-pay; Utility; Willingness-to-pay; Erlotinib; Gefitinib; Cost; Lung cancer; Lung disease; Costs; Enzyme; Respiratory disease; Transferases; Malignant tumor; non-small cell lung carcinoma; Payment; Epidermal growth factor; Health economy; Bronchus disease; Inhibitor; Protein-tyrosine kinase; Willingness to pay; Public health; Non small cell carcinoma
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2005.08.005

Oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are new agents in the treatment of advanced non-small cell lung cancer (NSCLC). Phase II studies demonstrate objective tumor responses and symptom improvement, combined with minimal toxicity and the convenience of an oral agent. We evaluated patient utility through willingness-to-pay (WTP) for these agents in the treatment of advanced NSCLC in Canada. Advanced NSCLC patients and healthy subjects participated in a structured interview and bidding exercise, reviewing current evidence supporting EGFR TKI therapy in advanced NSCLC and patient willingness-to-pay for treatment. Fifty-seven patients and 54 healthy subjects participated. The median amount both groups were willing to pay for a month of oral EGFR TKI therapy was $100 CAD (range $0–5000 per month). A minority of NSCLC patients received employment income, the majority relying on disability, pension income, and social assistance for financial support. Affordability of these agents was a key concern for both advanced NSCLC patients and healthy subjects. Univariate predictors of WTP included marital status, prior chemotherapy treatment, receiving pension income or financial social assistance. In multivariate analysis, only prior chemotherapy remained a significant predictor of WTP ( p = 0.049). Both advanced NSCLC patients and healthy subjects feel oral EGFR TKIs are worth paying for in the treatment of advanced NSCLC, but are willing to pay only a fraction of the market price. As many advanced NSCLC patients are financially disadvantaged, the potential for restricted access to newer therapies is of concern.